Press Releases
  Date Title View
May 17, 2017
Pooled analyses of Phase 1 expansion cohorts demonstrate clinically meaningful activity in patient population being studied in FORWARD I registration trial Top-line data from FORWARD II indicate favorable safety and efficacy profile in multiple combinations Conference call...
PDF
May 5, 2017
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Activated in North America and Europe Data at AACR and SGO Annual Meetings Highlight Patient Selection Strategy for FORWARD I and Breadth of ADC Expertise Mirvetuximab Soravtansine Safety and Efficacy Data to be Presented at ...
PDF
May 1, 2017
Data informed dosing in expansion cohorts and Phase 3 FORWARD I registration trial WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the resu...
PDF
Apr 21, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 5, 2017 to discuss its first quarter 2017 financial...
PDF
Mar 12, 2017
Data Confirm Use of Archival Tumor Tissue to Determine Patient Selection in FORWARD I WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that data ...
PDF
Mar 1, 2017
Nine presentations featuring the Company's leadership in ADCs WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that nine abstracts highlighting the breadt...
PDF
Feb 17, 2017
First Patient Enrolled in Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Continued Momentum in 2017 with Data Expected from Pipeline Programs Conference Call to be Held at 8:00am ET Today WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc...
PDF
Feb 2, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: ...
PDF
Jan 26, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been dosed in FORWARD I, the Company's Phase 3 clinical trial evaluating mirvetuximab soravtansine a...
PDF
Jan 25, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 17, 2017, to discuss ImmunoGen's financial res...
PDF
Jan 23, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Sandra Poole, Executive Vice President, Technical Operations and Commercial Development, will leave the Company at the end...
PDF
Dec 28, 2016
Positive Results Form Basis for FORWARD I Phase 3 Registration Trial WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the Phase ...
PDF
Dec 28, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 35th Annual J. P. Morgan Healthcare Conference in San Francisco. Th...
PDF
Dec 5, 2016
Data Demonstrate Activity in Acute Myeloid Leukemia Models While Sparing Normal Bone Marrow WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that precl...
PDF
Nov 11, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced new preclinical data that demonstrate the potential for enhanced activity when combining mirvetuximab soravtansine with immune ...
PDF
Nov 3, 2016
Includes Oral Presentation on CD123-Targeting ADC IMGN632 WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new preclinical data on the Company's nove...
PDF
Oct 28, 2016
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine On Track to Begin before Year End FORWARD II Trial Assessing Mirvetuximab Soravtansine Combinations with Avastin®, Carboplatin, Doxil®, and Keytruda® Ongoing Strategic Review Completed to Strengthen Underl...
PDF
Oct 14, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 28, 2016, to discuss ImmunoGen's financial resu...
PDF
Sep 29, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of a strategic review of its operations. As a result of this initiative, the Company will reduce its workforce b...
PDF
Aug 9, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Charles Morris, MBChB, MRCP, Executive Vice President and Chief Development Officer, is leaving the Company effec...
PDF
1
... NextLast

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue